Understand the medicine
What semaglutide is, and what the names mean
Semaglutide is a man-made version of GLP-1, a hormone the gut releases after eating.
A hormone is a chemical signal; GLP-1 helps control appetite and blood sugar.
The copy is changed to last about a week, rather than minutes.
In the U.S., both tablet and shot forms of semaglutide (Ozempic, Wegovy) have approvals as of September 2026.
To review a medicine, the U.S. Food and Drug Administration (FDA) looks at that product for one particular use.
FDA approval means the agency reviewed evidence that the exact medicine works and is safe enough for a named use.
Ozempic
Type 2 diabetes is a blood-sugar condition; Ozempic’s September 2026 label covers treatment for adults who have it.
Weight loss is outside Ozempic’s approved uses as of September 2026.
Wegovy
Wegovy’s U.S. approvals include weight care, alongside food and activity changes, as of September 2026.
Under its September 2026 label, adult weight care covers obesity, or excess weight with a linked health problem.
As of September 2026, a prescriber may use an approved medicine for a purpose the FDA has not approved.
This is called off-label prescribing.
Ask which product is being discussed, what it is meant to treat, and why that choice fits your health.
Understand the evidence
What weight-loss results can tell you
The adults in STEP 1 had no diabetes; they had either obesity or excess weight plus a health problem related to their weight.
The 68-week result was an average loss of 14.9% of body weight for semaglutide; people given the dummy shot averaged a 2.4% loss.
The dummy shot had no study medicine in it, and both groups had support with food and activity.
The trial’s funding came from Novo Nordisk, which makes the medicine.
In a follow-up to STEP 1, participants regained about two-thirds of their lost weight in the year after treatment stopped.
Ask for a plan for ongoing care, and a plan for what happens if treatment ends.
Arrange the care
Where to get care, and how to check it
Care can start with an in-person practice or telehealth, which means a visit using video, phone or an online exchange.
The health professional carrying out your assessment is called a clinician. A prescriber is someone allowed to write the medicine order, called a prescription.
For semaglutide, federal law has no requirement for a visit in person before prescribing, as of September 2026.
State rules and the care you need can still require one.
During an online visit, your location determines which state must permit the clinician to treat you, through a licence or another form of permission, under September 2026 rules.
Before the visit: check the names
For a doctor, the state medical board’s records show licence status and any public action over the doctor’s conduct.
Get the full name of whoever makes the medicine decision, along with their licence details. Ask whether this person is a doctor or another health professional. Ask which state board holds their licence record, and whether a doctor will be involved.
Find the state medical boardFor a pharmacy, the FDA’s lookup page links to state licence searches.
Ask which pharmacy will send the medicine, then check that exact name.
Open the pharmacy licence lookupAt the visit: make room for questions
The thyroid is the body part named in the Wegovy label’s warning about tumors that may cause a lump in the neck.
Wegovy’s label rules out treatment after medullary thyroid cancer in either you or a family member; this cancer is rare.
If you do not know which cancer a relative had, ask the clinician to check the exact name in the medical records.
Past trouble with the pancreas, the organ named in the label’s belly-pain warning, also matters to the review.
That warning describes inflammation, which means swelling.
Past trouble with the gallbladder, the organ affected by gallstones, also matters.
The review also needs to cover severe stomach problems and eye damage from diabetes.
Pregnancy plans matter to that review, too.
Other diabetes medicines and any planned surgery also belong in that review.
Bring your medicine list and any records of past belly illness, along with what you want help with. Ask whether any details are missing from the assessment and whether an exam or tests would help.
After the visit: know how to reach help
Ask how to get treatment questions answered, how follow-up is arranged, and how a change in the care plan would be handled. Keep the medicine name and the care plan together.
Make space for health cautions
What to discuss before treatment, and what to watch for
In the adult trials in Wegovy’s September 2026 label, 44% on semaglutide felt sick to their stomach, versus 16% on a dummy shot.
Loose stools, vomiting and trouble passing stools were also common in those trials.
Severe stomach problems can cause dehydration—loss of too much fluid—and kidney injury, according to the Wegovy label.
Thyroid tumors in the label
The strongest FDA alert—a boxed warning—appears on semaglutide labels for thyroid tumors.
These tumors appeared in rats and mice, but it is unknown whether semaglutide can cause thyroid tumors in people.
Medullary thyroid cancer is rare; a history of it in you or a relative means the label excludes treatment.
It also rules out use with MEN 2, a rare health condition that can run in families.
Keep that exact name in your questions. Ask the clinician to check your family health records and explain what the condition means for your care.
The medicine is also ruled out after a severe allergic reaction to semaglutide or any of its other ingredients.
Pregnancy and surgery
For a planned pregnancy, Wegovy’s label directs the prescriber to end treatment a minimum of two months beforehand.
Semaglutide makes the stomach empty more slowly.
For planned surgery, its label calls for telling the surgical team about the medicine.
Ask the team how they want to handle it.
Check the product claims
Pharmacy-made versions need a closer look
With semaglutide, compounding means preparing medicine to order instead of taking a drug maker’s finished product.
Pharmacy-made medicines receive neither FDA approval nor the agency’s checks of quality, benefit and safety ahead of sale, as of September 2026.
An approved medicine may leave a particular medical need unanswered; compounding can help fill that gap, subject to September 2026 legal limits.
In February 2025, the FDA said the national shortage of semaglutide shots had ended.
The FDA’s stated plan afterward was to delay action on copying-rule violations tied to that shortage.
That extra time ended in spring 2025.
Under the September 2026 rules, a pharmacy cannot regularly make a near-identical copy of a medicine already available.
For one named patient, a prescriber can document how changing the medicine makes an important medical difference.
That change can keep the medicine from counting as a copy under this rule.
A lower price alone is not an important medical difference under the September 2026 rules.
As of September 2026, an FDA national-shortage listing cannot be assumed just because one pharmacy has run out.
No prescription required
Federal law in September 2026 makes it unlawful to dispense a medicine that requires a prescription unless the prescription is valid.
Claimed to be an approved copy
A brand-name medicine’s approved copy is called a generic.
No FDA-approved generic semaglutide was on the U.S. market in September 2026.
Calling a compounded version FDA-approved is false under the September 2026 rules.
A research label
For research-labelled semaglutide sold for people to use, the FDA’s September 2026 advice is to stay away: the quality is uncertain, and using it could cause harm.
Sodium or acetate after the name
Semaglutide sodium and semaglutide acetate are salt forms, meaning different chemical versions of semaglutide.
The FDA’s position in September 2026 was that it knew no lawful route for including these salt forms in pharmacy-made medicines.
No clear source or follow-up
The FDA warns about unclear pharmacy details and about having no clinician to answer questions once the medicine arrives.
Reports recorded by the FDA as of September 2026 describe dosing mistakes involving compounded semaglutide; some patients needed hospital care.
Have the pharmacist or prescriber go over any medicine directions that you find unclear.
Weigh the next step
What it costs, and what to ask before paying
Start with the whole bill: the medicine, visits, any membership, tests and delivery. Ask for the regular charge as well as the opening offer.
The published price
List price means the drug maker’s published price; it can differ from the amount a person pays.
Wegovy’s published September 2026 list price came to about $1,349 a package; Ozempic’s list price was about $1,000.
Cash payment
For semaglutide in September 2026, the maker offered monthly cash prices of $149 to $499.
The product and strength determined the price.
The low shot offers applied only to eligible new patients’ first two monthly supplies of medicine.
Those offer terms ran through December 31, 2026, and the maker reserved the right to change or end them.
Ask for the exact product price and the cost after any offer ends.
Insurance payment
A formulary is the list telling you which medicines a plan covers.
When a plan needs to approve payment for a medicine in advance, that step is called prior authorization.
Ask whether your exact medicine and treatment purpose are covered, what approval is needed, and what you would pay.
The Bridge is scheduled to run until December 31, 2027.
Its September 2026 rules limit who qualifies by age, weight, health and Medicare plan.
A prescription and approval to pay for the medicine are needed first.
People who have type 2 diabetes are ineligible for the Bridge under September 2026 rules.
For them, semaglutide coverage is checked through their regular Medicare drug plan.
The regular Medicare drug plan limits your yearly spending on covered medicines under its September 2026 terms.
The $50 paid each month for Bridge medicine does not count toward that cap.
Those Bridge terms provide no additional cost help for members with low incomes.
Ask the prescriber and plan whether the Bridge or your regular drug coverage applies, and what approval you need.
Read the Medicare Bridge rulesKeep the conversation yours
Questions to take to a visit
Pick the questions that matter most to you. It is fine to bring them on paper and request another explanation of a term.
- Which semaglutide product is this, and what are we treating?
- Why does this option fit my health, and what else could fit?
- What in my health history or medicine list changes the choice?
- What will we check as care continues?
- Which symptoms need a call to the care team or urgent help?
- Which pharmacy sends the medicine, and how can I check its licence?
- What is the whole cost after any opening offer ends?
- Who answers my questions between visits?
- What is the plan if treatment ends?
Further reading
A short reading list, with a reason for each link
Open the item that answers your next question. The full study or medicine information can be dense; a clinician can help explain the part that matters to your care.
For approved uses and health cautions
Wegovy: the official medicine information
Start with the parts on uses and health cautions. Keep your questions beside the text.
For reading a result in context
The main weight-loss study
Look at who took part, the average result, and the comparison with a dummy shot.
For the longer-term conversation
Weight after treatment ended
Use this follow-up paper when asking what the plan would be if treatment stops.
For checking product claims
FDA: pharmacy-made versions
Read this alongside an advert. Compare what the advert says with the medicine name on its label.
For checking help with medicine costs
Medicare: the Bridge program
Read the rules on who qualifies with your prescriber and plan. Ask whether you can use the program.
For checking the offer terms
Government cash-offer pages
Read past the headline. Match the offer to the exact product, then ask about the full cost of care.